{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:39:41Z","timestamp":1789580381479,"version":"build-2803163510"},"reference-count":112,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Nerve growth factor (NGF), the first neurotrophin to be discovered, has a long and eventful research journey with a series of turning points, setbacks, and achievements. Since the groundbreaking investigations led by Nobel Prize winner Rita Levi-Montalcini, advancements in the comprehension of NGF\u2019s functions have revolutionized the field of neuroscience, offering new insights and opportunities for therapeutic innovation. However, the clinical application of NGF has historically been hindered by challenges in determining appropriate dosing, administration strategies, and complications related to the production process. Recent advances in the production and scientific knowledge of recombinant NGF have enabled its clinical development, and in 2018, the United States Food and Drug Administration approved cenegermin-bkbj, a recombinant human NGF, for the treatment of all stages of neurotrophic keratitis. This review traces the evolutionary path that transformed NGF from a biological molecule into a novel therapy with potential research applications beyond the eye. Special emphasis is put on the studies that advanced NGF from discovery to the first medicinal product approved to treat a human disease.<\/jats:p>","DOI":"10.3390\/biom14060635","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T06:35:32Z","timestamp":1717137332000},"page":"635","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The History of Nerve Growth Factor: From Molecule to Drug"],"prefix":"10.3390","volume":"14","author":[{"given":"Elizabeth","family":"Gavioli","sequence":"first","affiliation":[{"name":"Domp\u00e9 U.S. Inc., 181 2nd Avenue, STE 600, San Mateo, CA 94401, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Mantelli","sequence":"additional","affiliation":[{"name":"Domp\u00e9 farmaceutici S.p.A., Via Santa Lucia, 6, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-2985","authenticated-orcid":false,"given":"Maria Candida","family":"Cesta","sequence":"additional","affiliation":[{"name":"Domp\u00e9 farmaceutici S.p.A., Via Santa Lucia, 6, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sacchetti","sequence":"additional","affiliation":[{"name":"Domp\u00e9 farmaceutici S.p.A., Via Santa Lucia, 6, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-0233","authenticated-orcid":false,"given":"Marcello","family":"Allegretti","sequence":"additional","affiliation":[{"name":"Domp\u00e9 farmaceutici S.p.A., Via Santa Lucia, 6, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"ref_1","unstructured":"Levi-Montalcini, R. (2013). Elogio Dell\u2019imperfezione, Baldini + Castoldi."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jnr.490320402","article-title":"Function and Evolution in the Ngf Family and Its Receptors","volume":"32","author":"Ebendal","year":"1992","journal-title":"J. Neurosci. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.3306916","article-title":"The Nerve Growth Factor 35 Years Later","volume":"237","year":"1987","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.tcb.2004.05.011","article-title":"Rita Levi-Montalcini: The Discovery of Nerve Growth Factor and Modern Neurobiology","volume":"14","author":"Aloe","year":"2004","journal-title":"Trends Cell Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cytogfr.2007.04.004","article-title":"Nerve Growth Factor and Tissue Repair Remodeling: Trka(Ngfr) and P75(Ntr), Two Receptors One Fate","volume":"18","author":"Micera","year":"2007","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0166-2236(92)90047-C","article-title":"The Nerve Growth Factor Family of Receptors","volume":"15","author":"Meakin","year":"1992","journal-title":"Trends Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(90)90107-Q","article-title":"Binding of Brain-Derived Neurotrophic Factor to the Nerve Growth Factor Receptor","volume":"4","author":"Dechant","year":"1990","journal-title":"Neuron"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/j.1460-2075.1992.tb05130.x","article-title":"Binding of Neurotrophin-3 to Its Neuronal Receptors and Interactions with Nerve Growth Factor and Brain-Derived Neurotrophic Factor","volume":"11","author":"Dechant","year":"1992","journal-title":"EMBO J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0896-6273(94)90223-2","article-title":"Trk Receptors Use Redundant Signal Transduction Pathways Involving Shc and Plc-Gamma 1 to Mediate Ngf Responses","volume":"12","author":"Stephens","year":"1994","journal-title":"Neuron"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1479-5876-10-239","article-title":"Nerve Growth Factor: From the Early Discoveries to the Potential Clinical Use","volume":"10","author":"Aloe","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","article-title":"Trk Receptors: Roles in Neuronal Signal Transduction","volume":"72","author":"Huang","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1042\/bj3140951","article-title":"Cellular Processing of the Nerve Growth Factor Precursor by the Mammalian Pro-Protein Convertases","volume":"314","author":"Seidah","year":"1996","journal-title":"Biochem. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1126\/science.1065057","article-title":"Regulation of Cell Survival by Secreted Proneurotrophins","volume":"294","author":"Lee","year":"2001","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1471-4159.2008.05698.x","article-title":"Human Prongf: Biological Effects and Binding Profiles at Trka, P75ntr and Sortilin","volume":"107","author":"Clewes","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0022-2836(91)90655-P","article-title":"Crystallization and Characterization of the High Molecular Weight Form of Nerve Growth Factor (7 S Ngf)","volume":"219","author":"McDonald","year":"1991","journal-title":"J. Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ehf2.13138","article-title":"Pleiotropic Activity of Nerve Growth Factor in Regulating Cardiac Functions and Counteracting Pathogenesis","volume":"8","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"C360","DOI":"10.1152\/ajpcell.00180.2019","article-title":"The Pleiotropic Molecule Ngf Regulates the in Vitro Properties of Fibroblasts, Keratinocytes, and Endothelial Cells: Implications for Wound Healing","volume":"318","author":"Gostynska","year":"2020","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2174\/1570159X13666150403231920","article-title":"Nerve Growth Factor: A Focus on Neuroscience and Therapy","volume":"13","author":"Aloe","year":"2015","journal-title":"Curr. Neuropharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fnins.2019.00533","article-title":"Nerve Growth Factor Pathobiology During the Progression of Alzheimer\u2019s Disease","volume":"13","author":"Mufson","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/08820538.2021.1890793","article-title":"Nerve Growth Factor as an Ocular Therapy: Applications, Challenges, and Future Directions","volume":"36","author":"Kanu","year":"2021","journal-title":"Semin. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1073\/pnas.40.10.1014","article-title":"A Nerve Growth-Stimulating Factor Isolated from Sarcom as 37 and 180","volume":"40","author":"Cohen","year":"1954","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.42.9.571","article-title":"In Vitro and in Vivo Effects of a Nerve Growth-Stimulating Agent Isolated from Snake Venom","volume":"42","author":"Cohen","year":"1956","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1073\/pnas.46.3.373","article-title":"xcessive Growth of the Sympathetic Ganglia Evoked by a Protein Isolated from Mouse Salivary Glands","volume":"46","author":"Booker","year":"1960","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.143.3602.105","article-title":"Growth Control of Nerve Cells by a Protein Factor and Its Antiserum: Discovery of This Factor May Provide New Leads to Understanding of Some Neurogenetic Processes","volume":"143","year":"1964","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0166-2236(96)10058-8","article-title":"Nerve Growth Factor: From Neurotrophin to Neurokine","volume":"19","author":"Skaper","year":"1996","journal-title":"Trends Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1073\/pnas.64.2.787","article-title":"The Nerve Growth Factor: Purification as a 30,000-Molecular-Weight Protein","volume":"64","author":"Bocchini","year":"1969","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbapap.2014.12.005","article-title":"A Comparative Analysis of the Structural, Functional and Biological Differences between Mouse and Human Nerve Growth Factor","volume":"1854","author":"Paoletti","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnins.2019.00038","article-title":"Innovative Therapy for Alzheimer\u2019s Disease-with Focus on Biodelivery of Ngf","volume":"13","author":"Mitra","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00702-003-0091-x","article-title":"Alzheimer\u2019s Disease and Ngf Signaling","volume":"111","author":"Salehi","year":"2004","journal-title":"J. Neural Transm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s10571-020-00993-1","article-title":"Nerve Growth Factor Is a Potential Treated Target in Tg(Sod1*G93a)1gur Mice","volume":"42","author":"Xu","year":"2022","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archneur.1991.00530160037011","article-title":"Intraputaminal Infusion of Nerve Growth Factor to Support Adrenal Medullary Autografts in Parkinson\u2019s Disease: One-Year Follow-up of First Clinical Trial","volume":"48","author":"Olson","year":"1991","journal-title":"Arch. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Keefe, K.M., Sheikh, I.S., and Smith, G.M. (2017). Targeting Neurotrophins to Specific Populations of Neurons: Ngf, Bdnf, and Nt-3 and Their Relevance for Treatment of Spinal Cord Injury. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18030548"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jcms.2018.03.015","article-title":"Evaluation of Nerve Growth Factor (Ngf) Treated Mesenchymal Stem Cells for Recovery in Neurotmesis Model of Peripheral Nerve Injury","volume":"46","author":"Moattari","year":"2018","journal-title":"J. Craniomaxillofac. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2174\/0929867327999200818111654","article-title":"Nerve Growth Factor, Stress and Diseases","volume":"28","author":"Ceci","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/PRBM.S104814","article-title":"Mental Disorders, Functional Impairment, and Nerve Growth Factor","volume":"10","author":"Salles","year":"2017","journal-title":"Psychol. Res. Behav. Manag."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gul, M.K., Sahin, M., Demirci, E., Ozmen, S., Tahtasakal, R., and Sener, E.F. (2023). Nerve Growth Factor and Angiotensin Converting Enzyme 2 Levels in Children with Neurodevelopmental Disorders. Int. J. Neurosci., 1\u20137.","DOI":"10.1080\/00207454.2023.2257871"},{"key":"ref_37","first-page":"4","article-title":"Nerve Growth Factor in the Psychiatric Brain","volume":"55","author":"Ciafre","year":"2020","journal-title":"Riv. Psichiatr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1097\/j.pain.0000000000001625","article-title":"Nerve Growth Factor Antibody for the Treatment of Osteoarthritis Pain and Chronic Low-Back Pain: Mechanism of Action in the Context of Efficacy and Safety","volume":"160","author":"Schmelz","year":"2019","journal-title":"Pain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/acs.jmedchem.6b00964","article-title":"Targeting the Nerve Growth Factor (Ngf) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain","volume":"60","author":"Norman","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105966","DOI":"10.1016\/j.pep.2021.105966","article-title":"Preparation and Characterization of a High-Af Fi Nity Monoclonal Antibody against Nerve Growth Factor","volume":"189","author":"Liu","year":"2022","journal-title":"Protein Expr. Purif."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s11011-022-00974-x","article-title":"Ngf\/Trka Promotes the Vitality, Migration and Adhesion of Bone Marrow Stromal Cells in Hypoxia by Regulating the Nrf2 Pathway","volume":"37","author":"Fang","year":"2022","journal-title":"Metab. Brain Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13469","DOI":"10.1073\/pnas.0906678106","article-title":"Experimental and Clinical Evidence of Neuroprotection by Nerve Growth Factor Eye Drops: Implications for Glaucoma","volume":"106","author":"Lambiase","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","first-page":"439","article-title":"Nerve Growth Factor Eye Drops Improve Visual Acuity and Electrofunctional Activity in Age-Related Macular Degeneration: A Case Report","volume":"45","author":"Lambiase","year":"2009","journal-title":"Ann. Ist. Super. Sanita"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.burns.2022.11.001","article-title":"Nerve Growth Factor and Burn Wound Healing: Update of Molecular Interactions with Skin Cells","volume":"49","author":"Dosh","year":"2023","journal-title":"Burns"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Liu, P., Li, S., and Tang, L. (2021). Nerve Growth Factor: A Potential Therapeutic Target for Lung Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179112"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1515\/REVNEURO.2009.20.2.133","article-title":"Nerve Growth Factor as a Signaling Molecule for Nerve Cells and Also for the Neuroendocrine-Immune Systems","volume":"20","author":"Fiore","year":"2009","journal-title":"Rev. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/cancers3010510","article-title":"Nerve Growth Factor in Cancer Cell Death and Survival","volume":"3","author":"Molloy","year":"2011","journal-title":"Cancers"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ferraguti, G., Fanfarillo, F., Tarani, L., Blacona, G., Tarani, F., Barbato, C., Minni, A., Ralli, M., Francati, S., and Greco, A. (2022). Ngf and the Male Reproductive System: Potential Clinical Applications in Infertility. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113127"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/molehr\/gav057","article-title":"The Importance of Neuronal Growth Factors in the Ovary","volume":"22","author":"Streiter","year":"2016","journal-title":"Mol. Hum. Reprod."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0166-4328(93)90141-C","article-title":"Intracranial Infusion of Purified Nerve Growth Factor to an Alzheimer Patient: The First Attempt of a Possible Future Treatment Strategy","volume":"57","author":"Seiger","year":"1993","journal-title":"Behav. Brain Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000017069","article-title":"Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer\u2019s Disease","volume":"9","author":"Nordberg","year":"1998","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(99)02784-1","article-title":"Effect of Topical Application of Nerve-Growth Factor on Pressure Ulcers","volume":"354","author":"Bernabei","year":"1999","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"635","DOI":"10.7326\/0003-4819-139-8-200310210-00006","article-title":"Topical Treatment of Pressure Ulcers with Nerve Growth Factor: A Randomized Clinical Trial","volume":"139","author":"Landi","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0140-6736(00)03212-8","article-title":"Ngf, a Tool in the Treatment of Chronic Vasculitic Ulcers in Rheumatoid Arthritis","volume":"356","author":"Tuveri","year":"2000","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1055\/s-2004-821313","article-title":"Topical Application of Nerve Growth Factor in Human Diabetic Foot Ulcers. A Study of Three Cases","volume":"112","author":"Generini","year":"2004","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1124\/jpet.120.000110","article-title":"Effects of Topical Application of Chf6467, a Mutated Form of Human Nerve Growth Factor, on Skin Wound Healing in Diabetic Mice","volume":"375","author":"Giuliani","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/B978-0-444-53480-4.00020-5","article-title":"Epidermal Innervation in Diabetes","volume":"126","author":"Ebenezer","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/FOC-07\/11\/E2","article-title":"Optic Pathway Gliomas: A Review","volume":"23","author":"Binning","year":"2007","journal-title":"Neurosurg. Focus"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/brain\/awv366","article-title":"Nerve Growth Factor Improves Visual Loss in Childhood Optic Gliomas: A Randomized, Double-Blind, Phase Ii Clinical Trial","volume":"139","author":"Falsini","year":"2016","journal-title":"Brain"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/1545968310395601","article-title":"Nerve Growth Factor Eye Drop Administration Improves Visual Function in a Patient with Optic Glioma","volume":"25","author":"Chiaretti","year":"2011","journal-title":"Neurorehabil. Neural Repair."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/1545968310397201","article-title":"Topical Nerve Growth Factor as a Visual Rescue Strategy in Pediatric Optic Gliomas: A Pilot Study Including Electrophysiology","volume":"25","author":"Falsini","year":"2011","journal-title":"Neurorehabil. Neural Repair."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1212\/01.wnl.0000435745.95155.b8","article-title":"Functional Outcome Measures for Nf1-Associated Optic Pathway Glioma Clinical Trials","volume":"81","author":"Fisher","year":"2013","journal-title":"Neurology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-neuro-072116-031121","article-title":"Nerve Growth Factor and Pain Mechanisms","volume":"40","author":"Denk","year":"2017","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"105662","DOI":"10.1016\/j.phrs.2021.105662","article-title":"Understanding Pain Perception through Genetic Painlessness Diseases: The Role of Ngf and Prongf","volume":"169","author":"Testa","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9702","DOI":"10.1523\/JNEUROSCI.0688-19.2019","article-title":"The Ngfr100w Mutation Specifically Impairs Nociception without Affecting Cognitive Performance in a Mouse Model of Hereditary Sensory and Autonomic Neuropathy Type V","volume":"39","author":"Testa","year":"2019","journal-title":"J. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jbspin.2018.09.009","article-title":"Targeting Nerve Growth Factor to Relieve Pain from Osteoarthritis: What Can We Expect?","volume":"86","author":"Berenbaum","year":"2019","journal-title":"Jt. Bone Spine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/art.41674","article-title":"Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Non-Steroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial","volume":"73","author":"Hochberg","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Zhou, N., Gu, T., Xu, Y., Liu, Y., and Peng, L. (2023). Challenges and Progress of Neurodrug: Bioactivities, Production and Delivery Strategies of Nerve Growth Factor Protein. J. Biol. Eng., 17.","DOI":"10.1186\/s13036-023-00392-2"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"104240","DOI":"10.1016\/j.phrs.2019.04.024","article-title":"Pharmacology of Nerve Growth Factor and Discovery of Tanezumab, an Anti-Nerve Growth Factor Antibody and Pain Therapeutic","volume":"154","author":"Hefti","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"695592","DOI":"10.3389\/fnins.2021.695592","article-title":"Nerve Growth Factor Biodelivery: A Limiting Step in Moving toward Extensive Clinical Application?","volume":"15","author":"Alastra","year":"2021","journal-title":"Front. Neurosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1212\/WNL.54.5.1080","article-title":"A Phase Ii Trial of Nerve Growth Factor for Sensory Neuropathy Associated with Hiv Infection. Aids Clinical Trials Group Team 291","volume":"54","author":"McArthur","year":"2000","journal-title":"Neurology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0301-0082(96)00010-X","article-title":"Neurotrophic Factors in Peripheral Neuropathies: Pharmacological Strategies","volume":"49","author":"Riaz","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.284.17.2215","article-title":"Efficacy and Safety of Recombinant Human Nerve Growth Factor in Patients with Diabetic Polyneuropathy: A Randomized Controlled Trial. Rhngf Clinical Investigator Group","volume":"284","author":"Apfel","year":"2000","journal-title":"Jama"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0074-7742(02)50083-0","article-title":"Nerve Growth Factor for the Treatment of Diabetic Neuropathy: What Went Wrong, What Went Right, and What Does the Future Hold?","volume":"50","author":"Apfel","year":"2002","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_75","unstructured":"(2023, December 15). Domp\u00e9. Available online: https:\/\/www.dompe.com\/us\/who-we-are\/about-us."},{"key":"ref_76","unstructured":"ClinicalTrials.gov (2023, December 15). Defendo Long Term Follow-up Study in Stage 1 Nk Patients (Defendo), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05552261."},{"key":"ref_77","unstructured":"ClinicalTrials.gov (2023, December 15). Study to Evaluate Oxervate\u2122 in Patients with Stage 1 Neurotrophic Keratitis (Defendo), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04485546?term=NCT04485546&rank=1."},{"key":"ref_78","unstructured":"ClinicalTrials.gov (2023, December 15). Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate\u00ae) vs. Vehicle in Severe Sjogren\u2019s Dry Eye Disease (Ngf0221\u2014Protego-2 Study) (Ngf0221), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05136170?term=NCT05136170&rank=1."},{"key":"ref_79","unstructured":"ClinicalTrials.gov (2023, December 15). Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate\u00ae) vs. Vehicle in Severe Sjogren\u2019s Dry Eye Disease (Ngf0121\u2014Protego-1 Study) (Ngf0121), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05133180?term=NCT05133180&rank=1."},{"key":"ref_80","unstructured":"ClinicalTrials.gov (2023, December 15). A Study to Evaluate Safety and Efficacy of Rhngf Eye Solution vs. Vehicle in Patients with Moderate to Severe Dry Eye, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03982368?term=NCT03982368&rank=1."},{"key":"ref_81","unstructured":"ClinicalTrials.gov (2023, December 15). A 8 Weeks Study to Evaluate Efficacy & Safety of Rhngf vs. Vehicle in Patients after Cataract and Refractive Surgery, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03035864?term=NCT03035864&rank=1."},{"key":"ref_82","unstructured":"ClinicalTrials.gov (2023, December 15). An 8-Week Study to Evaluate Safety and Efficacy of Ngf Eye Drops Solution Versus Vehicle in Patients with Dry Eye, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03019627?term=NCT03019627&rank=1."},{"key":"ref_83","unstructured":"ClinicalTrials.gov (2023, December 15). Nerve Growth Factor Eye Drops Treatment in Patients with Retinitis Pigmentosa and Cystoid Macular Edema (Nemo), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02609165?term=NCT02609165&rank=1."},{"key":"ref_84","unstructured":"ClinicalTrials.gov (2023, December 15). Evaluation of Efficacy of 20 \u00b5g\/mL Rhngf New Formulation (with Anti-Oxidant) in Patients with Stage 2 and 3 Nk, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02227147?term=NCT02227147&rank=1."},{"key":"ref_85","unstructured":"ClinicalTrials.gov (2023, December 15). Safety and Efficacy of Rhngf Eye Drops at Different Doses in Patients with Dry Eye, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02101281?term=NCT02101281&rank=1."},{"key":"ref_86","unstructured":"ClinicalTrials.gov (2023, December 15). A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of Rhngf in Patients with Retinitis Pigmentosa (Rp) (Lumos), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02110225?term=NCT02110225&rank=1."},{"key":"ref_87","unstructured":"ClinicalTrials.gov (2023, December 15). Evaluation of Safety and Efficacy of Rhngf in Patients with Stage 2 and 3 Neurotrophic Keratitis. (Reparo), Available online: https:\/\/clinicaltrials.gov\/study\/NCT01756456?term=NCT01756456&rank=1."},{"key":"ref_88","unstructured":"ClinicalTrials.gov (2023, December 15). Study to Evaluate Safety and Efficacy of Rhngf Eye Drops Solution Versus Vehicle in Patients with Glaucoma (Ngf-Glaucoma), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02855450?term=NCT02855450&rank=1."},{"key":"ref_89","unstructured":"ClinicalTrials.gov (2023, December 15). Ngf Treatment for Patients with Neuropathic Corneal Pain, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05700864?term=NCT05700864&rank=1."},{"key":"ref_90","unstructured":"ClinicalTrials.gov (2023, December 15). Study to Evaluate Safety, Tolerability & Pk of Rhngf in Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03836859?term=NCT03836859&rank=1."},{"key":"ref_91","unstructured":"ClinicalTrials.gov (2023, December 15). Study to Evaluate Safety, Tolerability and Pharmacokinetics of Rhngf Eye Drops in Healthy Volunteers (Ngf0112), Available online: https:\/\/clinicaltrials.gov\/study\/NCT01744704?term=NCT01744704&rank=1."},{"key":"ref_92","unstructured":"ClinicalTrials.gov (2023, December 15). The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft vs. Host Disease (Gvhd) Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04700657?term=NCT04700657&rank=1."},{"key":"ref_93","unstructured":"ClinicalTrials.gov (2023, December 15). Corneal Nerves after Treatment with Cenegermin, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04627571?term=NCT04627571&rank=1."},{"key":"ref_94","unstructured":"ClinicalTrials.gov (2023, December 15). Oct Evaluation of Neurotrophic Ulcer Following Treatment with Oxervate, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04573647?term=NCT04573647&rank=1."},{"key":"ref_95","unstructured":"ClinicalTrials.gov (2023, December 15). Nerve Growth Factor for the Treatment of Cornea Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04552730?term=NCT04552730&rank=1."},{"key":"ref_96","unstructured":"The Portal for Rare Diseases and Orphan Drugs (2023, December 14). Neurotrophic Keratopathy, Available online: https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=EN&Expert=137596."},{"key":"ref_97","unstructured":"National Organization for Rare Disorders (2024, February 20). Neurotrophic Keratitis. Available online: https:\/\/rarediseases.org\/rare-diseases\/neurotrophic-keratitis\/."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000354380","article-title":"Neurotrophic Keratitis","volume":"231","author":"Semeraro","year":"2014","journal-title":"Ophthalmologica"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.ophtha.2018.03.004","article-title":"Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis","volume":"125","author":"Bonini","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","article-title":"Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis","volume":"125","author":"Bonini","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","article-title":"Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial","volume":"127","author":"Pflugfelder","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_102","unstructured":"Pr Newswire (2023, December 15). Domp\u00e9 Announces First Treatment with Oxervate\u2122 Eye Drops (Cenegermin-Bkbj), for Neurotrophic Keratitis (Nk). Available online: https:\/\/www.prnewswire.com\/news-releases\/dompe-announces-first-treatment-with-oxervate-eye-drops-cenegermin-bkbj-for-neurotrophic-keratitis-nk-300772376.html."},{"key":"ref_103","unstructured":"(2018). Oxervate (Cenegermin-Bkbj) [Package Insert], Dompe, US Inc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/ICO.0000000000002974","article-title":"Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy-Biologicals as a Novel Therapy for Neurotrophic Keratopathy","volume":"41","author":"Hamrah","year":"2022","journal-title":"Cornea"},{"key":"ref_105","unstructured":"Mantelli, F. (2023, December 15). Nerve Growth Factor: From Discovery to Development for Human Use. Available online: https:\/\/www.optometrytimes.com\/view\/nerve-growth-factor-from-discovery-to-development-for-human-use."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/ICO.0000000000001865","article-title":"Sj\u00f6gren\u2019s Syndrome: More Than Just Dry Eye","volume":"38","author":"Akpek","year":"2019","journal-title":"Cornea"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Gujar, V., Pande, R.D., and Das, S. (2024). Nerve Growth Factor Shows Biphasic Expression during Adjuvant-Induced Neurogenic Inflammation. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202403.0036.v1"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Minnone, G., De Benedetti, F., and Bracci-Laudiero, L. (2017). Ngf and Its Receptors in the Regulation of Inflammatory Response. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18051028"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8950","DOI":"10.3390\/cimb45110562","article-title":"Nerve Growth Factor and Autoimmune Diseases","volume":"45","author":"Terracina","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"773","DOI":"10.4103\/1673-5374.354513","article-title":"Intranasal Nerve Growth Factor for Prevention and Recovery of the Outcomes of Traumatic Brain Injury","volume":"18","author":"Manni","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Curatola, A., Graglia, B., Granata, G., Conti, G., Capossela, L., Manni, L., Ferretti, S., Di Giuda, D., Romeo, D.M., and Calcagni, M.L. (2023). Combined Treatment of Nerve Growth Factor and Transcranical Direct Current Stimulations to Improve Outcome in Children with Vegetative State after out-of-Hospital Cardiac Arrest. Biol. Direct, 18.","DOI":"10.1186\/s13062-023-00379-5"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Gatto, A., Capossela, L., Conti, G., Eftimiadi, G., Ferretti, S., Manni, L., Curatola, A., Graglia, B., Di Sarno, L., and Calcagni, M.L. (2023). Intranasal Human-Recombinant Ngf Administration Improves Outcome in Children with Post-Traumatic Unresponsive Wakefulness Syndrome. Biol. Direct, 18.","DOI":"10.1186\/s13062-023-00418-1"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/6\/635\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:50:02Z","timestamp":1760107802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/6\/635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":112,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["biom14060635"],"URL":"https:\/\/doi.org\/10.3390\/biom14060635","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}